Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco January DIC 600x60px
Document › Details

Pieris Pharmaceuticals, Inc.. (8/9/17). "Press Release: Pieris Pharmaceuticals Reports Financial Results for the Second Quarter Ended June 30, 2017 and Provides Corporate Update". Boston, MA.

Organisations Organisation Pieris Pharmaceuticals Inc. (Nasdaq: PIRS)
  Group Pieris (Group)
  Organisation 2 AstraZeneca plc (LSE: AZN)
  Group AstraZeneca (Group)
Products Product Anticalin® scaffold technology
  Product 2 PRS-060/AZD1402 (anti-IL4Ra Anticalin, Pieris/AstraZeneca)
Index term Index term AstraZeneca–Pieris: anticalin technology, 201705– collab developm + commerc $57.5m upfront + near-term inhaled respiratory drugs incl PRS-060
Persons Person Yoder, Stephen S. (Steve) (Pieris 201001– CEO before MorphoSys Head Licensing + IP)
  Person 2 Brkulj, Mario (MacDougall 201511 VP before MorphoSys + Biocom)
     


   
Record changed: 2017-08-18

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Investors 600x60px

More documents for Pieris (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco January DIC 600x60px




» top